Schizophrenia

Measurement of premorbid adjustment in chronic schizophrenia.

Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull. 1982;8(3):470-84. PubMed PMID: 7134891.

Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia.

Semiz UB, Cetin M, Basoglu C, Ebrinc S, Uzun O, Herken H, et al. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(6):1330-6. DOI: 10.1016/j.pnpbp.2007.06.002. PubMed PMID: 17618026.

Predictors of response in a sample of treatment-resistant psychotic patients on clozapine.

Ciapparelli A, Ducci F, Carmassi C, Carlini M, Paggini R, Catena M, et al. Predictors of response in a sample of treatment-resistant psychotic patients on clozapine. Eur Arch Psychiatry Clin Neurosci. 2004;254(5):343-6. DOI: 10.1007/s00406-004-0511-4. PubMed PMID: 15365711.

Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine.

Masellis M, Basile VS, Ozdemir V, Meltzer HY, Macciardi FM, Kennedy JL. Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine. Biol Psychiatry. 2000;47(3):252-66. PubMed PMID: 10682223.

Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients.

Masellis M, Basile V, Meltzer HY, Lieberman JA, Sevy S, Macciardi FM, et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology. 1998;19(2):123-32. DOI: 10.1016/S0893-133X(98)00007-4. PubMed PMID: 9629566.

Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine.

Malhotra AK, Goldman D, Ozaki N, Breier A, Buchanan R, Pickar D. Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. Am J Psychiatry. 1996;153(8):1092-4. PubMed PMID: 8678181.

No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response.

Bolonna AA, Arranz MJ, Munro J, Osborne S, Petouni M, Martinez M, et al. No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response. Neurosci Lett. 2000;280(1):65-8. PubMed PMID: 10696813.

Genetic predictors of therapeutic response to clozapine: current status of research.

Mancama D, Arranz MJ, Kerwin RW. Genetic predictors of therapeutic response to clozapine: current status of research. CNS Drugs. 2002;16(5):317-24. PubMed PMID: 11994021.

Genetic Sources of Subcomponents of Event-Related Potential in the Dimension of Psychosis Analyzed From the B-SNIP Study.

Narayanan B, Ethridge LE, O'Neil K, Dunn S, Mathew I, Tandon N, et al. Genetic Sources of Subcomponents of Event-Related Potential in the Dimension of Psychosis Analyzed From the B-SNIP Study. Am J Psychiatry. 2015;172(5):466-78. DOI: 10.1176/appi.ajp.2014.13101411. PubMed PMID: 25615564.

N-Methyl-d-aspartate receptor autoantibodies in schizophrenia and affective disorders.

Steiner J, Bogerts B. N-Methyl-d-aspartate receptor autoantibodies in schizophrenia and affective disorders. Schizophr Res. 2015;162(1-3):291. DOI: 10.1016/j.schres.2015.01.009. PubMed PMID: 25600550.